<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="openVirus\examples\priya950\4-part\PMC7258707\results\search\disease\results.xml">
  <result pre="therapies approved by the Food and Drug Administration for countering" exact="anthrax" post="and under development for treatment of Ebola virus infection"/>
  <result pre="by the US Army. Keywords therapeutics biothreat pathogens antibacterial antiviral" exact="anthrax" post="Ebola 1 Introduction The concept of bioterrorism and the"/>
  <result pre="coronaviruses Severe acute respiratory distress CNipah and Hendra viruses Viral" exact="encephalitis" post="and respiratory disease ARift Valley fever virus Rift Valley"/>
  <result pre="acute respiratory distress CNipah and Hendra viruses Viral encephalitis and" exact="respiratory disease" post="ARift Valley fever virus Rift Valley fever BVenezuelan equine"/>
  <result pre="disease ARift Valley fever virus Rift Valley fever BVenezuelan equine" exact="encephalitis" post="virus Encephalitis and fever ALassa virus Lassa fever ASouth"/>
  <result pre="spore-forming bacterium that causes cutaneous, respiratory, or intestinal forms of" exact="anthrax" post="disease, which is an acute, rapidly progressing infection in"/>
  <result pre="aerosol route, thus making it a dangerous bacterium [7]. The" exact="anthrax" post="attacks in 2001 caused widespread panic, damage, disease, and"/>
  <result pre="the early stage of the infection. Two monoclonal antibody (mAB)–based" exact="anthrax" post="antitoxin therapeutics [Abthrax (raxibacumab) and Anthim (obiltoxaximab)] have been"/>
  <result pre="and included in the Strategic National Stockpile for treating inhalational" exact="anthrax" post="[8]. BioThrax, the only licensed anthrax vaccine, is indicated"/>
  <result pre="Stockpile for treating inhalational anthrax [8]. BioThrax, the only licensed" exact="anthrax" post="vaccine, is indicated for preexposure prophylaxis of disease in"/>
  <result pre="Intravenous, human-derived antibotulism toxin antibodies for the treatment of infant" exact="botulism" post="types A and B, and Botulism Antitoxin Heptavalent (A–G),"/>
  <result pre="The nonmotile bacillus B. mallei is the causative agent of" exact="glanders" post="that usually infects equids but is highly infectious to"/>
  <result pre="to persistent infections. F. tularensis is the causative agent of" exact="tularemia" post="and is highly infectious, resulting in an acute, rapidly"/>
  <result pre="virus (VARV) is the causative agent of smallpox, a human" exact="viral disease" post="for which tecovirimat was recently approved as a therapeutic"/>
  <result pre="are also biothreat concerns. For the alphaviruses specifically, the Venezuelan" exact="encephalitis" post="viruses (VEEV), Eastern encephalitis viruses, and Western equine encephalitis"/>
  <result pre="For the alphaviruses specifically, the Venezuelan encephalitis viruses (VEEV), Eastern" exact="encephalitis" post="viruses, and Western equine encephalitis viruses belonging to the"/>
  <result pre="Venezuelan encephalitis viruses (VEEV), Eastern encephalitis viruses, and Western equine" exact="encephalitis" post="viruses belonging to the family Togaviridae are found in"/>
  <result pre="from GPs of viruses such as Ebola, Nipah, Hendra, and" exact="severe acute respiratory syndrome" post="and Middle East respiratory syndrome coronavirus and containing Cat"/>
  <result pre="positron emission tomography; RSV, respiratory syncytial virus; TP, triphosphate; VEEV," exact="venezuelan equine encephalitis" post="virus. Table 7.4 Antiviral therapeutics (small molecules, antibodies, and"/>
  <result pre="tomography; RSV, respiratory syncytial virus; TP, triphosphate; VEEV, venezuelan equine" exact="encephalitis" post="virus. Table 7.4 Antiviral therapeutics (small molecules, antibodies, and"/>
  <result pre="F. tularensis LVS could be successfully used to treat LVS-induced" exact="pneumonia" post="but not a F. tularensis type A strain. Anti-LVS"/>
  <result pre="extracellular virion NHP: prophylactic antibody treatment can protect against severe" exact="monkeypox" post="disease in marmoset model [148] PoxviridaeVariola MultipleMV, H3, A27,"/>
  <result pre="effective than antibiotics alone in a rabbit model of inhalational" exact="anthrax" post="and improved survival compared to the antibiotic treatment alone"/>
  <result pre="treatment alone [155] Ciprofloxacin Clindamycin Treatment of rabbits with systemic" exact="anthrax" post="with clindamycin and ciprofloxacin had improved efficacy compared to"/>
  <result pre="antiprotective antigen (PA IgG) antibodies and ciprofloxacin in a rodent" exact="anthrax" post="model increased survival significantly compared to ciprofloxacin treatment alone"/>
  <result pre="10-fold lower development of resistance compared to antibiotics used for" exact="anthrax" post="treatment in humans [159] Penicillin, meropenem, or rifampin Linezolid"/>
  <result pre="[159] Penicillin, meropenem, or rifampin Linezolid Treatment of antibiotic-resistant inhalation" exact="anthrax" post="with linezolid and penicillin, meropenem, or rifampin had the"/>
  <result pre="fluoroquinolone-resistant B. anthracis infection [160] Rifampin Clindamycin Combination therapy for" exact="anthrax" post="with rifampin and clindamycin was shown to be synergistic"/>
  <result pre="spp. Doxycycline Rifampin Successful combination therapies used to treat pulmonary" exact="brucellosis" post="in humans is doxycycline and rifampin for 6 weeks"/>
  <result pre="using heat-killed B. mallei can protect BALB/c mice from lethal" exact="glanders" post="infection, potentially by stimulating immune responses, such as gamma"/>
  <result pre="for genetically diverse extremely drug resistant isolates of Burkholderia from" exact="cystic fibrosis" post="patients by binding PenA and the combination treatment significantly"/>
  <result pre="with Q fever endocarditis. And a case of Q fever" exact="endocarditis" post="with biological prosthetic aortic valve and aortic homograft was"/>
  <result pre="survival of rats following infection with Y. pestis [176] AIGIV," exact="anthrax" post="immune globulin intravenous; IFN, interferon; LPS, lipopolysaccharide; PA, protective"/>
  <result pre="(a breathing stimulant) mitigated fatal Y. pestis infection in a" exact="pneumonic plague" post="murine model [207]. At 48 h postinfection, these drugs"/>
  <result pre="breathing stimulant) mitigated fatal Y. pestis infection in a pneumonic" exact="plague" post="murine model [207]. At 48 h postinfection, these drugs"/>
  <result pre="with up to 100% protection against challenge with bubonic or" exact="pneumonic plague" post="agents when administered in combination with levofloxacin [208]. Multiple"/>
  <result pre="up to 100% protection against challenge with bubonic or pneumonic" exact="plague" post="agents when administered in combination with levofloxacin [208]. Multiple"/>
  <result pre="been shown to improve the efficacy of postexposure therapeutics against" exact="smallpox" post="[214]. Sometimes modulation of host pathophysiological responses can be"/>
  <result pre="under the FDA’s Animal Efficacy Rule for treatment of inhalation" exact="anthrax" post="[8]. For treatment of Ebola infection, the single mAb"/>
  <result pre="combination of nucleoside, nonnucleoside, protease, and/or host-targeted inhibitors) or chronic" exact="hepatitis" post="C virus infection (e.g., combination of polymerase and RNA-binding"/>
  <result pre="to reach infected tissue. For example, countermeasures against pathogens causing" exact="encephalitis" post="require drug to reach the central nervous system (CNS)."/>
  <result pre="products, including several therapeutics for anthrax, plague, botulinum toxin, and" exact="smallpox" post="[8], [29]. The Animal Rule does not provide an"/>
  <result pre="capabilities. Three FDA-approved drugs have shown potential in mice against" exact="pneumonic plague" post="[207]. Serious challenges still remain with the prevalence of"/>
  <result pre="Three FDA-approved drugs have shown potential in mice against pneumonic" exact="plague" post="[207]. Serious challenges still remain with the prevalence of"/>
  <result pre="Centers for Disease Control and Prevention EBOV Ebola virus EEEV" exact="eastern equine encephalitis" post="virus EF edema factor ELISA enzyme-linked immunosorbent assay EPEC"/>
  <result pre="Disease Control and Prevention EBOV Ebola virus EEEV eastern equine" exact="encephalitis" post="virus EF edema factor ELISA enzyme-linked immunosorbent assay EPEC"/>
  <result pre="target product profile US United States VARV variola virus VEEV" exact="venezuelan equine encephalitis" post="virus VGCC voltage-gated calcium channel VLP virus-like particle WEEV"/>
  <result pre="profile US United States VARV variola virus VEEV venezuelan equine" exact="encephalitis" post="virus VGCC voltage-gated calcium channel VLP virus-like particle WEEV"/>
  <result pre="VGCC voltage-gated calcium channel VLP virus-like particle WEEV Western equine" exact="encephalitis" post="virus Y2H yeast two-hybrid References References 1GreenM.S.LeDucJ.CohenD.FranzD.R.Confronting the threat"/>
  <result pre="anti-plague monoclonal antibodies protect mice from Yersinia pestis in a" exact="bubonic plague" post="modelPLoS One5102010e1304720976274 23NakkaziE.Randomised controlled trial begins for Ebola therapeuticsLancet392101622018233830527603"/>
  <result pre="monoclonal antibodies protect mice from Yersinia pestis in a bubonic" exact="plague" post="modelPLoS One5102010e1304720976274 23NakkaziE.Randomised controlled trial begins for Ebola therapeuticsLancet392101622018233830527603"/>
  <result pre="of tecovirimat for the treatment of smallpoxLancet Infect Dis1962019e221e22430853252 31KupferschmidtK.Labmade" exact="smallpox" post="is possible, study showsScience3576347201711511628706017 32DupuyL.C.SchmaljohnC.S.DNA vaccines for biodefenseExpert Rev"/>
  <result pre="of a small-molecule entry inhibitor for filovirusesJ Virol85720113106311921270170 53XiaoJ.H.RijalP.SchimanskiL.TharkeshwarA.K.WrightE.AnnaertW.Characterization of" exact="influenza" post="virus pseudotyped with ebolavirus glycoproteinJ Virol9242018 54BaeS.E.KimS.S.MoonS.T.ChoY.D.LeeH.LeeJ.Y.Construction of the"/>
  <result pre="drugsSci Rep912019539730932009 67ElshabrawyH.A.FanJ.HaddadC.S.RatiaK.BroderC.C.CaffreyM.Identification of a broad-spectrum antiviral small molecule against" exact="severe acute respiratory syndrome" post="coronavirus and Ebola, Hendra, and Nipah viruses by using"/>
  <result pre="host proteins important for entry of Marburg virus and H5N1" exact="influenza" post="virusVirol J12201519426596270 82DeffrasnesC.MarshG.A.FooC.H.RootesC.L.GouldC.M.GrusovinJ.Genome-wide siRNA screening at biosafety level 4"/>
  <result pre="plasma concentrations to improve treatment response in patients with chronic" exact="hepatitis" post="CJ Antimicrob Chemother62620081174118018931138 115UckunF.M.PetkevichA.S.VassilevA.O.TibblesH.E.TitovL.Stampidine prevents mortality in an experimental"/>
  <result pre="related thereto2015 119JonssonC.B.CaoX.LeeJ.GabbardJ.D.ChuY.K.FitzpatrickE.A.Efficacy of a ML336 derivative against Venezuelan and" exact="eastern equine encephalitis" post="virusesAntiviral Res1672019253430970271 120SchroederC.E.YaoT.SotskyJ.SmithR.A.RoyS.ChuY.K.Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as"/>
  <result pre="119JonssonC.B.CaoX.LeeJ.GabbardJ.D.ChuY.K.FitzpatrickE.A.Efficacy of a ML336 derivative against Venezuelan and eastern equine" exact="encephalitis" post="virusesAntiviral Res1672019253430970271 120SchroederC.E.YaoT.SotskyJ.SmithR.A.RoyS.ChuY.K.Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as"/>
  <result pre="120SchroederC.E.YaoT.SotskyJ.SmithR.A.RoyS.ChuY.K.Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of" exact="venezuelan equine encephalitis" post="virusJ Med Chem572020148608862125244572 121FlorescuD.F.KalilA.C.HewlettA.L.SchuhA.J.StroherU.UyekiT.M.Administration of brincidofovir and convalescent plasma"/>
  <result pre="(E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine" exact="encephalitis" post="virusJ Med Chem572020148608862125244572 121FlorescuD.F.KalilA.C.HewlettA.L.SchuhA.J.StroherU.UyekiT.M.Administration of brincidofovir and convalescent plasma"/>
  <result pre="and therapy against Nipah virus infection in hamstersJ Virol80420061972197816439553 148MuckerE.M.Wollen-RobertsS.E.KimmelA.ShamblinJ.SampeyD.HooperJ.W.Intranasal" exact="monkeypox" post="marmoset model: Prophylactic antibody treatment provides benefit against severe"/>
  <result pre="monkeypox marmoset model: Prophylactic antibody treatment provides benefit against severe" exact="monkeypox" post="virus diseasePLoS Negl Trop Dis1262018e000658129927927 149BregenholtS.JensenA.LanttoJ.HyldigS.HaurumJ.S.Recombinant human polyclonal antibodies:"/>
  <result pre="not purified in mosquitoesJ Virol881520148213822624829346 155KammanadimintiS.PatnaikuniR.K.ComerJ.MeisterG.SinclairC.KodihalliS.Combination therapy with antibiotics and" exact="anthrax" post="immune globulin intravenous (AIGIV) is potentially more effective than"/>
  <result pre="anthraxPLoS One992014e10639325226075 156WeissS.AltboumZ.GlinertI.SchlomovitzJ.SittnerA.Bar-DavidE.Efficacy of single and combined antibiotic treatments of" exact="anthrax" post="in rabbitsAntimicrob Agents Chemother591220157497750326392505 157KarginovV.A.RobinsonT.M.RiemenschneiderJ.GoldingB.KennedyM.ShiloachJ.Treatment of anthrax infection with"/>
  <result pre="antibiotic treatments of anthrax in rabbitsAntimicrob Agents Chemother591220157497750326392505 157KarginovV.A.RobinsonT.M.RiemenschneiderJ.GoldingB.KennedyM.ShiloachJ.Treatment of" exact="anthrax" post="infection with combination of ciprofloxacin and antibodies to protective"/>
  <result pre="160HeineH.S.ShadomyS.V.BoyerA.E.ChuvalaL.RigginsR.KestersonA.Evaluation of combination drug therapy for treatment of antibiotic-resistant inhalation" exact="anthrax" post="in a murine modelAntimicrob Agents Chemother6192017 161AthamnaA.AthamnaM.NuraA.ShlyakovE.BastD.J.FarrellD.Is in vitro"/>
  <result pre="reviewExpert Rev Anti Infect Ther1512017334227790937 163WaagD.M.Efficacy of postexposure therapy against" exact="glanders" post="in miceAntimicrob Agents Chemother59420152236224125645854 164SaqibM.MuhammadG.NaureenA.HussainM.H.AsiM.N.MansoorM.K.Effectiveness of an antimicrobial treatment"/>
  <result pre="Chemother59420152236224125645854 164SaqibM.MuhammadG.NaureenA.HussainM.H.AsiM.N.MansoorM.K.Effectiveness of an antimicrobial treatment scheme in a confined" exact="glanders" post="outbreakBMC Vet Res8201221423134717 165BrilhanteR.S.ValenteL.G.RochaM.F.BandeiraT.J.CordeiroR.A.LimaR.A.Sesquiterpene farnesol contributes to increased susceptibility"/>
  <result pre="restores susceptibility to ceftazidime for burkholderia cepacia complex isolates from" exact="cystic fibrosis" post="patientsACS Infect Dis37201750251128264560 167MosovskyK.SilvaE.TroyerR.Propst-GrahamK.DowS.Interaction of Interferon gamma-induced reactive oxygen"/>
  <result pre="evolution of Burkholderia pseudomallei during chronic infection of seven Australasian" exact="cystic fibrosis" post="patientsMBio822017 187WebbJ.R.PriceE.P.CurrieB.J.SarovichD.S.Loss of methyltransferase function and increased efflux activity"/>
  <result pre="214IsraelyT.MelamedS.AchdoutH.ErezN.PolitiB.WanerT.TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live" exact="smallpox" post="vaccinesPLoS One9102014e11054525350003 215LeeA.Y.VlasukG.P.Recombinant nematode anticoagulant protein c2 and other"/>
 </snippets>
</snippetsTree>
